...
首页> 外文期刊>Stem cells and development >Neonatal desensitization supports long-term survival and functional integration of human embryonic stem cell-derived mesenchymal stem cells in rat joint cartilage without immunosuppression
【24h】

Neonatal desensitization supports long-term survival and functional integration of human embryonic stem cell-derived mesenchymal stem cells in rat joint cartilage without immunosuppression

机译:新生儿脱敏支持人类胚胎干细胞来源的间充质干细胞在大鼠关节软骨中的长期存活和功能整合,而无需进行免疫抑制

获取原文
获取原文并翻译 | 示例
           

摘要

Immunological response hampers the investigation of human embryonic stem cells (hESCs) or their derivates for tissue regeneration in vivo. Immunosuppression is often used after surgery, but exhibits side effects of significant weight loss and allows only short-term observation. The purpose of this study was to investigate whether neonatal desensitization supports relative long-term survival of hESC-derived mesenchymal stem cells (hESC-MSCs) and promotes cartilage regeneration. hESC-MSCs were injected on the day of birth in rats. Six weeks after neonatal injection, a full-thickness cylindrical cartilage defect was created and transplanted with a hESC-MSC-seeded collagen bilayer scaffold (group d+s+c) or a collagen bilayer scaffold (group d+s). Rats without neonatal injection were transplanted with the hESC-MSC-seeded collagen bilayer scaffold to serve as controls (group s+c). Cartilage regeneration was evaluated by histological analysis, immunohistochemical staining, and biomechanical test. The role of hESC-MSCs in cartilage regeneration was analyzed by CD4 immunostaining, cell death detection, and visualization of human cells in regenerated tissues. hESC-MSCs expressed CD105, CD73, CD90, CD29, and CD44, but not CD45 and CD34, and possessed trilineage differentiation potential. Group d+s+c exhibited greater International Cartilage Repair Society (ICRS) scores than group d+s or group s+c. Abundant collagen type II and improved mechanical properties were detected in group d+s+c. There were less CD4+ inflammatory cell infiltration and cell death at week 1, and hESC-MSCs were found to survive as long as 8 weeks after transplantation in group d+s+c. Our study suggests that neonatal desensitization before transplantation may be an efficient way to develop a powerful tool for preclinical study of human cell-based therapies in animal models.
机译:免疫应答阻碍了人类胚胎干细胞(hESCs)或其衍生物在体内组织再生方面的研究。免疫抑制通常在手术后使用,但会表现出明显的体重减轻的副作用,并且只能进行短期观察。这项研究的目的是调查新生儿脱敏是否支持hESC来源的间充质干细胞(hESC-MSCs)的相对长期存活并促进软骨再生。在出生当天在大鼠中注射hESC-MSC。新生儿注射后六周,创建了一个全层圆柱形软骨缺损,并移植了hESC-MSC种植的胶原双层支架(d + s + c组)或胶原双层支架(d + s组)。未注射新生鼠的大鼠移植了hESC-MSC种子胶原双层支架,作为对照组(s + c组)。通过组织学分析,免疫组织化学染色和生物力学测试评估软骨的再生。 hESC-MSC在软骨再生中的作用已通过CD4免疫染色,细胞死亡检测和再生组织中人细胞的可视化进行了分析。 hESC-MSC表达CD105,CD73,CD90,CD29和CD44,但不表达CD45和CD34,并具有三系分化潜能。 d + s + c组的国际软骨修复协会(ICRS)得分高于d + s组或s + c组。在d + s + c组中检测到大量的II型胶原蛋白和改善的机械性能。 d + s + c组在第1周时CD4 +炎性细胞浸润和细胞死亡较少,并且发现hESC-MSC可以存活到移植后8周。我们的研究表明,在移植前进行新生儿脱敏可能是一种有效的方法,可以为动物模型中基于人细胞的疗法的临床前研究开发强大的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号